A cut-off point will improve the usefulness of the MHI-5 to a great extent, for example for screening mental health problems in primary care or for calculating a health expectancy based on mental health [ 21, 22].
In several cancers, including ovarian cancer, it has been demonstrated that the expression of a specific subset of miRNAs may potentially be used in clinical practice, for example, for screening or early diagnosis to evaluate the response to therapeutic treatments [ 91, 92].
These include resonant structures with electronic actuation and electronic measurement, having good quality factors for plastic-based devices, and high-resolution masks (∼10 μm) which can be used, for example, for screen-printing techniques.
This approach would, for example, be useful for screening individuals with uncertain CNVs recorded in on-line databases such as Decipher (Firth et al. 2009).
For example, screening for GALNT6 inhibitors would be valuable for development of novel therapeutic modalities against breast cancer, since over-expression of GALNT6 might contribute to mammary carcinogenesis [ 24].
For example, screening for binding elements in RNA sequences comparable to the approach implemented for the PTBs, Nova, and Pumilio in this study could be readily performed for any RBP of interest.
For example, screening for PSA is likely to be correlated among counties when the screening initiative is directed toward a large area.
For example, screening for diabetes in pregnancy is not available in all facilities, particularly in Africa [ 2], and therefore underestimation of gestational diabetes is likely.
For example, screening for albuminuria was not done in many of the patients and hence this was not included in our analysis.
For example, screening for colorectal cancer has been shown to be cost effective and also more importantly to reduce mortality [ 31].
These predictions will be especially important when tumors are found at very early stages — for example, after screening for prostate cancer with the P.S.A. test, for breast cancer with mammography or M.R.I.'s, or for lung cancer with CT scans.
